Effects of β-glucan from Aureobasidium pullulans in a Streptozotocininduced Rat Diabetes Model

Author(s): Jae-Hak Sohn, Joo Wan Kim, Jong-Min Lim, Go-Woon Jung, Sae Kwang Ku*, Jae-Suk Choi*

Journal Name: Current Nutrition & Food Science

Volume 16 , Issue 7 , 2020


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: The alleviating effects of diabetic nephropathy and hepatopathy of β-glucan were evaluated in this study.

Objective: The anti-diabetic effects of β -glucan from Aureobasidium pullulans were assessed in a streptozotocin (STZ)-induced rat diabetes model at 62.5 and 125 mg/kg doses. In addition, the possibility of changes in the effects of β-glucan according to the severity of diabetes was also assessed at one dosage (62.5 mg/kg): severe, >360 mg/dL; slight, 130-200 mg/dL.

Methods: Test articles were administered orally to STZ-induced diabetic rats from 21 days after STZ dosing for 4 weeks. Each of five or six female rats per group was selected using blood glucose levels at 21 days after STZ dosing. Changes in body weight were recorded during the study, along with blood glucose, blood urea nitrogen, creatinine, and serum aspartate aminotransferase and alanine aminotransferase levels. On the day of sacrifice, livers and kidneys were weighed and observed microscopically for changes in the percentage of degenerative regions and numbers of degenerative tubules in the kidney.

Results: β-glucan showed no hypoglycemic effects in the STZ-induced diabetic rat model. However, it had favorable effects on decreasing diabetic complications related to diabetic nephropathy and hepatopathy.

Conclusion: Based on the results of this study, it was concluded that β-glucan showed favorable effects in decreasing diabetic complications in STZ-induced rat diabetes model.

Keywords: Diabetic hepatopathy, diabetic nephropathy, rats, β-glucan, streptozotocin, aureobasidium pullulans.

[1]
Malaguti-Boyle M. Evidence for the effectiveness of clinical nutrition therapy in diabetes mellitus type 2. J Aust Tradit-Med Soc 2016; 22: 74-82.
[2]
Norris SL, Engelgau MM, Narayan KM. Effectiveness of self-management training in type 2 diabetes: a systematic review of randomized controlled trials. Diabetes Care 2001; 24(3): 561-87.
[http://dx.doi.org/10.2337/diacare.24.3.561] [PMID: 11289485]
[3]
Kuzuya T, Nakagawa S, Satoh J, et al. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res Clin Pract 2002; 55(1): 65-85.
[http://dx.doi.org/10.1016/S0168-8227(01)00365-5] [PMID: 11755481]
[4]
Bell S, Goldman VM, Bistrian BR, Arnold AH, Ostroff G, Forse RA. Effect of β-glucan from oats and yeast on serum lipids. Crit Rev Food Sci Nutr 1999; 39(2): 189-202.
[http://dx.doi.org/10.1080/10408399908500493] [PMID: 10198754]
[5]
Seo HP, Kim JM, Shin HD, et al. Production of β-1,3/1,6-glucan by Aureobasidium pullulans SM-2001. Kor J Bitechnol Bioeng 2002; 17: 376-80.
[6]
Othman RA, Moghadasian MH, Jones PJ. Cholesterol-lowering effects of oat β-glucan. Nutr Rev 2011; 69(6): 299-309.
[http://dx.doi.org/10.1111/j.1753-4887.2011.00401.x] [PMID: 21631511]
[7]
El Khoury D, Cuda C, Luhovyy BL, et al. Beta glucan: Health benefits in obesity and metabolic syndrome. J Nutr Metab 2012; 2012851362
[8]
Kim YH, Paek JY, Shin HW, Han MD. Single dose toxicity studies of sulfated water soluble β-D-glucan in Sprague-Dawley rats. J Environ Biol 2012; 33(6): 1107-14.
[PMID: 23741810]
[9]
Vijayakumar L, Ramalingam P. Physico-chemical characterization of β-glucan produced from LVK13. J Environ Biol 2016; 37: 1535-8.
[10]
Akramiene D, Kondrotas A, Didziapetriene J, Kevelaitis E. Effects of beta-glucans on the immune system. Medicina (Kaunas) 2007; 43(8): 597-606.
[http://dx.doi.org/10.3390/medicina43080076] [PMID: 17895634]
[11]
Soltanian S, Stuyven E, Cox E, Sorgeloos P, Bossier P. Beta-glucans as immunostimulant in vertebrates and invertebrates. Crit Rev Microbiol 2009; 35(2): 109-38.
[http://dx.doi.org/10.1080/10408410902753746] [PMID: 19514911]
[12]
Bashir KMI, Choi JS. Clinical and Physiological perspectives of β-glucans: the past, present and future. Int J Mol Sci 2017; 18: 1906.
[13]
Parving HH, Andersen AR, Smidt UM, Svendsen PA. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983; 1(8335): 1175-9.
[http://dx.doi.org/10.1016/S0140-6736(83)92462-5] [PMID: 6133986]
[14]
Kurtz TW, Pravenec M. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. J Hypertens 2004; 22(12): 2253-61.
[http://dx.doi.org/10.1097/00004872-200412000-00003] [PMID: 15614015]
[15]
González E, Roselló-Catafau J, Jawerbaum A, et al. Pancreatic nitric oxide and oxygen free radicals in the early stages of streptozotocin-induced diabetes mellitus in the rat. Braz J Med Biol Res 2000; 33(11): 1335-42.
[http://dx.doi.org/10.1590/S0100-879X2000001100012] [PMID: 11050665]
[16]
Kamata K, Kobayashi T. Changes in superoxide dismutase mRNA expression by streptozotocin-induced diabetes. Br J Pharmacol 1996; 119(3): 583-9.
[http://dx.doi.org/10.1111/j.1476-5381.1996.tb15712.x] [PMID: 8894182]
[17]
Coskun O, Ocakci A, Bayraktaroglu T, Kanter M. Exercise training prevents and protects streptozotocin-induced oxidative stress and beta-cell damage in rat pancreas. Tohoku J Exp Med 2004; 203(3): 145-54.
[http://dx.doi.org/10.1620/tjem.203.145] [PMID: 15240923]
[18]
Quine SD, Raghu PS. Effects of (-)-epicatechin, a flavonoid on lipid peroxidation and antioxidants in streptozotocin-induced diabetic liver, kidney and heart. Pharmacol Rep 2005; 57(5): 610-5.
[PMID: 16227644]
[19]
Sathishsekar D, Subramanian S. Beneficial effects of Momordica charantia seeds in the treatment of STZ-induced diabetes in experimental rats. Biol Pharm Bull 2005; 28(6): 978-83.
[http://dx.doi.org/10.1248/bpb.28.978] [PMID: 15930730]
[20]
Choi JS, Kim JW, Jung GW, et al. Hypoglycemic and hypolipemic effect of β-glucan originated from Aureobasidium in STZ-induced diabetic rats. J Anim Plant Sci 2018; 28: 660-8.
[21]
Anjaneyulu M, Chopra K. Diltiazem attenuates oxidative stress in diabetic rats. Ren Fail 2005; 27(3): 335-44.
[http://dx.doi.org/10.1081/JDI-56630] [PMID: 15957552]
[22]
Guerrero-Analco JA, Hersch-Martínez P, Pedraza-Chaverri J, Navarrete A, Mata R. Antihyperglycemic effect of constituents from Hintonia standleyana in streptozotocin-induced diabetic rats. Planta Med 2005; 71(12): 1099-105.
[http://dx.doi.org/10.1055/s-2005-873137] [PMID: 16395644]
[23]
Ceriello A, Quatraro A, Giugliano D. New insights on non-enzymatic glycosylation may lead to therapeutic approaches for the prevention of diabetic complications. Diabet Med 1992; 9(3): 297-9.
[http://dx.doi.org/10.1111/j.1464-5491.1992.tb01783.x] [PMID: 1576819]
[24]
Hosseini A, Mollazadeh H, Amiri MS, Sadeghnia HR, Ghorbani A. Effects of a standardized extract of Rheum turkestanicum Janischew root on diabetic changes in the kidney, liver and heart of streptozotocin-induced diabetic rats. Biomed Pharmacother 2017; 86: 605-11.
[http://dx.doi.org/10.1016/j.biopha.2016.12.059] [PMID: 28027536]
[25]
Sodikoff CH. Laboratory Profiles of Small Animal Diseases A Guide to Laboratory Diagnosis St Louise. Mosby Inc. 1995.
[26]
Trachtman H, Futterweit S, Pine E, Mann J, Valderrama E. Chronic diabetic nephropathy: role of inducible nitric oxide synthase. Pediatr Nephrol 2002; 17(1): 20-9.
[http://dx.doi.org/10.1007/s004670200004] [PMID: 11793130]
[27]
Huang H, Jiang Y, Mao G, et al. Protective effects of allicin on streptozotocin-induced diabetic nephropathy in rats. J Sci Food Agric 2017; 97(4): 1359-66.
[http://dx.doi.org/10.1002/jsfa.7874] [PMID: 27363537]
[28]
Clark TA, Heyliger CE, Edel AL, Goel DP, Pierce GN. Codelivery of a tea extract prevents morbidity and mortality associated with oral vanadate therapy in streptozotocin-induced diabetic rats. Metabolism 2004; 53(9): 1145-51.
[http://dx.doi.org/10.1016/j.metabol.2004.03.017] [PMID: 15334376]
[29]
Shin JW, Seol IC, Son CG. Interpretation of animal dose and human equivalent dose for drug development. J Kor Orient Med 2010; 31: 1-7.


open access plus

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 7
Year: 2020
Published on: 09 September, 2020
Page: [1052 - 1063]
Pages: 12
DOI: 10.2174/1573401315666190904142801

Article Metrics

PDF: 58
HTML: 1